DCW shares fall 4.6% after Q1 deck shows 33% EBITDA drop, negative margin in Basic Chemicals

DCW Ltd’s stock fell 4.6% in the session after the company released its Q1-FY27 investor presentation, even as the topline showed healthy growth. The deck, dated 13 August 2026, underscored that the quarter was defined less by revenue momentum and more by a sharp squeeze in operating profitability and a weaker margin profile.

Revenue up 14%, but operating leverage breaks down

According to the Quarterly Consolidated Financial Performance table on page 13, DCW’s consolidated operational income for Q1-FY27 stood at ₹5,419 million, up from ₹4,755 million in Q1-FY26, a 14.0% year‑on‑year increase. The presentation (page 10) attributes this primarily to:

• 38% growth in the Specialty Chemicals segment
• 5% growth in Basic Chemicals

However, total expenses rose faster than revenue, climbing to ₹5,061 million in Q1-FY27 from ₹4,218 million a year earlier, a 20.0% increase (page 13). That cost inflation outpaced the 14.0% revenue growth and effectively broke the operating leverage that had supported margin expansion in FY24–FY26.

EBITDA down 33.3% YoY and margins compress sharply

The key negative surprise in the presentation is at the EBITDA line. As per page 13:

• EBITDA fell to ₹358 million in Q1-FY27 from ₹537 million in Q1-FY26, a (33.3)% year‑on‑year decline.
• EBITDA margin dropped to 6.61% from 11.29%, a contraction of 468 basis points year‑on‑year.
• Sequentially, EBITDA was down from ₹646 million in Q4-FY26, with margin falling from 10.61% to 6.61%, a 400 basis‑point decline.

This reversal stands out against the three‑year trend shown on page 17, where FY24–FY26 EBITDA margins had improved from 9.38% to 10.34%. The investor deck makes clear that Q1-FY27 broke that improving trajectory.

Why margins cracked: VCM disruption and PVC pressure

The Key Financial and Operational Highlights on page 10 explicitly spell out the headwinds that weighed on profitability:

• “Profitability during the quarter was impacted by the non-availability of VCM due to the West Asia crisis, elevated VCM prices, and the temporary suspension of PVC import duties, which adversely affected PVC realizations and margins.”

In other words, DCW faced a squeeze from both sides of the PVC chain:

• Feedstock shock: Non‑availability of VCM (vinyl chloride monomer) and elevated VCM prices raised input costs.
• Pricing pressure: The temporary suspension of PVC import duties hurt PVC realizations and margins, limiting DCW’s ability to pass on higher costs.

The same section notes that sequential revenue declined by 11% versus Q4-FY26 due to higher captive PVC consumption for CPVC, lower PVC production, and inventory liquidation in the Synthetic Rutile business. That combination of lower PVC volumes, weaker PVC pricing and higher feedstock costs is a clear negative for near‑term earnings quality and helps explain why the market focused on margins rather than revenue growth.

Segment mix: specialty strong, but not enough to offset basic weakness

The presentation highlights that Specialty Chemicals remained a relative bright spot:

• Page 10 states that Specialty Chemicals EBITDA grew 19.2% YoY, supported by higher C‑PVC volumes after the recent capacity expansion.
• The Quarterly Key Segmental Financial Performance chart on page 11 shows Specialty Chemicals revenue rising from ₹1,285 million in Q1-FY26 to ₹1,770 million in Q1-FY27, with segment EBITDA margins of 33.6%, 22.9% and 29.1% in Q1-FY26, Q4-FY26 and Q1-FY27 respectively.

By contrast, Basic Chemicals saw pressure:

• Basic Chemicals revenue moved from ₹3,424 million in Q1-FY26 to ₹3,609 million in Q1-FY27, but the segment EBITDA margin swung from 2.0% in Q1-FY26 and 5.6% in Q4-FY26 to (5.2)% in Q1-FY27 (page 11).

That negative margin in Basic Chemicals, driven largely by the PVC issues flagged in the commentary, more than offset the gains in Specialty Chemicals and pulled down consolidated EBITDA.

PAT boosted by tax line, masking weak pre‑tax performance

At first glance, bottom‑line growth looks impressive:

• Profit after tax (PAT) jumped to ₹345 million in Q1-FY27 from ₹114 million in Q1-FY26, a 202.6% year‑on‑year increase (page 10 and 13).
• PAT margin improved to 6.37% from 2.40%, a 397‑basis‑point expansion (page 13).
• Diluted EPS rose to ₹1.17 from ₹0.39, a 200.0% year‑on‑year increase (page 10 and 13).

But the pre‑tax picture tells a different story:

• Profit before tax (PBT) fell sharply to ₹4 million in Q1-FY27 from ₹177 million in Q1-FY26, a (97.7)% decline (page 13).
• The swing in tax – from an expense of ₹63 million in Q1-FY26 to a tax credit of ₹341 million in Q1-FY27 – drove the PAT jump (pages 13 and 15).

The historical income statement on page 15 shows a similar pattern for FY26, where PAT of ₹482 million on PBT of ₹746 million was supported by a ₹264 million tax line. The Q1-FY27 investor deck does not break out the nature of the Q1 tax credit beyond the numbers, but the sharp divergence between PBT and PAT suggests investors may be discounting the quality and sustainability of the bottom‑line growth.

Balance sheet improving, but near‑term earnings under scrutiny

On the structural side, DCW continues to show balance‑sheet improvement:

• The snapshot on page 2 cites a Net Debt to Equity Ratio of 0.07 and Net Debt to EBITDA Ratio of 0.32 as on FY26 end.
• Page 17 reiterates that Net Debt/EBITDA has fallen from 1.52 in FY24 to 1.09 in FY25 and 0.32 in FY26, while Net Debt/Equity has declined from 0.26 to 0.20 and then 0.07 over the same period.

The Q1 commentary on page 10 adds that “Net leverage continued to improve during the quarter and remains on track to turn net cash positive by the end of FY27, before undertaking any incremental debt for future growth initiatives.”

While this deleveraging story is positive, the market reaction suggests that investors are currently more focused on the abrupt deterioration in operating profitability and the external risks around VCM availability and PVC pricing.

Capex plan underscores long‑term specialty push

The Capital Expenditure slide on page 8 details DCW’s next growth phase:

• Total capex of ₹250 crore over the next 2–3 years for:
  • SIOP Phase I capacity addition of 7,000 MT, targeted for Q4-FY28.
  • Power Plant Efficiency Capex at Sahupuram, also targeted for Q4-FY28.

The company notes that “value added products in the pigment category will enter the market during FY28 alongside the construction and commissioning of Phase I growth.” This reinforces the long‑term shift toward higher‑margin specialty products, but the benefits are several years out, while the VCM/PVC headwinds are immediate.

Why the stock likely fell 4.6%

Given that the stock was flat before the filing and then declined 4.6% in the hours after, the investor presentation appears to be the main driver of the move. The deck combines:

• Solid 14.0% revenue growth and strong Specialty Chemicals performance;
• With a (33.3)% drop in EBITDA, a 468‑bps EBITDA margin compression, and a swing to (5.2)% EBITDA margin in Basic Chemicals;
• Plus a (97.7)% collapse in PBT to ₹4 million, with PAT growth driven by a large tax credit rather than core operations;
• And explicit commentary about VCM supply disruption, elevated VCM prices and weak PVC realizations due to temporary duty suspension.

Taken together, the filing signals that near‑term earnings are vulnerable to external commodity and policy factors, and that the apparent strength in PAT is not fully reflective of underlying operating performance. That disconnect between headline profit growth and weakening core profitability likely explains why the market marked the stock down despite the long‑term capex and deleveraging story.